Both are "veterans" who have worked at Johnson & Johnson for many years, making significant contributions to the company's growth.
Writing |Huang Siyu
Source丨Pharmaceutical Innovation
Johnson & Johnson's pharmaceutical innovation division, part of the pharmaceutical giant Johnson & Johnson, has recently undergone two significant personnel changes.According to reports from multiple industry media, Chen Jian, Vice President of Johnson & Johnson Innovative Pharmaceuticals China, Head of the Oncology Business Unit, and Market Access & Government Affairs, has been appointed as the Head of Commercial Operations & Innovative Diversity of Johnson & Johnson Innovative Pharmaceuticals China and General Manager of Johnson & Johnson Pharmaceutical Co., Ltd.
Chen Jian/Image Source: Johnson & Johnson Innovative Pharmaceuticals
Public information shows that Chen Jian worked at the Wuhan Institute for Drug Control in Hubei earlier in his career. In 1996, he chose to leave the system and join Xi'an Janssen, which was gaining momentum at the time.Xian Janssen is known as the "Whampoa Military Academy" of China's pharmaceuticals industry, where many executives of multinational pharmaceutical companies have launched their careers. At this company, Chen Jian has served as the head of the Oncology Business Unit, Vice President of the Innovative Product Division, and Vice President of Government Affairs and Market Access.In September 2023, Janssen Pharmaceuticals was renamed Johnson & Johnson Innovative Medicine. Subsequently, Chen Jian was promoted to Vice President of Johnson & Johnson Innovative Medicine in China, while continuing to serve as the head of the Oncology Business Unit, Market Access, and Government Affairs, until this new appointment.The oncology sector is one of the key areas of Johnson & Johnson's innovative pharmaceuticals. The company's 2024 financial report shows that the oncology business achieved an annual revenue of $20.781 billion, increasing by 17.7% year-on-year, accounting for 36% of the total revenue.Not long after the beginning of 2025, Johnson & Johnson has already achieved significant success in the Chinese market, with three new oncology drugs—erdafitinib, tebentafusp, and amivantamab—successively approved in China. Among them, tebentafusp is a First-in-class drug, and the approval of amivantamab marks Johnson & Johnson's official entry into the lung cancer treatment field in China. Johnson & Johnson's strong momentum in the oncology sector is expected to be maintained in the long term."The essence of innovative pharmaceutical companies is to continuously introduce innovative products to enhance patient benefits. Over the past 20 years, we have deeply cultivated the oncology field in China, focusing on 'First-in-class' product development, promoting more comprehensive solutions, and advancing towards the early stages of cancer. Our goal is to make cancer a controllable and curable chronic disease, and to lead the exploration of the possibility of curing cancer." Chen Jian said this at the 16th Health China Forum held in November last year.Sévan Kaloustian, who previously served as Vice President and Managing Director of Johnson & Johnson Innovative Pharmaceuticals' Jordan, Egypt, and North Africa (JENA) Cluster, has taken over from Chen Jian as the head of the Oncology Business Unit. Kaloustian is also a "veteran" with over a decade of experience at Johnson & Johnson.
Sévan Kaloustian/Image source: internet
Public information shows that Sévan Kaloustian is a Master of Pharmaceutical Economics and a Ph.D. in Pharmacology from the University of Montreal, Canada, and an associate professor at the university's School of Medicine. In 2009, he joined Johnson & Johnson, where he held positions in France, the United States, Poland, and other places, gradually growing from a regular medical specialist and sales representative to become the Global Commercial Strategy Director of one of Johnson & Johnson’s subsidiaries in New Jersey, USA.In November 2019, Sévan Kaloustian began leading Janssen Pharmaceuticals' operations in Romania. Upon taking office, he stated plans to bring several products in the fields of immunology, hematology, and neuroscience to the country, develop new CAR-T therapies, and work to accelerate the clinical trial process in Romania.Thereafter, he served as Vice President and Managing Director of Johnson & Johnson Innovative Pharmaceuticals for Jordan, Egypt, and North Africa, leading a professional team of over 200 members from multiple countries. He was dedicated to bringing innovative therapies to patients in these regions.According to reports from multiple industry media, Sévan Kaloustian will also serve as the Vice President of Johnson & Johnson Innovative Pharmaceuticals China, directly reporting to Huang Chen, President of Johnson & Johnson Innovative Pharmaceuticals China, which means he officially becomes a core member of the Johnson & Johnson Innovative Pharmaceuticals China management team.
*"Medical Community" strives to ensure that the content published is professional and reliable, but does not guarantee the accuracy of the content; relevant parties should verify independently when adopting or using it as a basis for decision-making.
